GlobeNewswire·Apr 16, 2026, 8:57 AM ET

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Life Sciences appointed Andrew D. Goldberg, MD, as Chief Executive Officer & Board member, effective upon closing of its financing.
New financing totals up to $354 million, comprising $180 million upfront & $174 million dependent on milestone warrant exercise.
Richard Stewart, outgoing President & CEO & co-founder, remains on the Board to support the transition.
Lucian Iancovici, MD (TPG) & Aaron E. Royston, MD (venBio) were appointed to the Board of Directors alongside the CEO change.
The FDA accepted Achieve's New Drug Application for cytisinicline in June 2025 & set a PDUFA review date of June 20, 2026.
Cytisinicline is an investigational plant-based alkaloid developed as the first potential new treatment for nicotine dependence in two decades.
The drug targets both combustible cigarette smoking cessation & e-cigarette vaping cessation, the latter having Breakthrough Therapy designation.
Two successful Phase 3 studies & an open-label safety study support the smoking cessation indication, while a Phase 2 study covered vaping.
Goldberg's background includes dual board certification in Critical Care & Emergency Medicine, plus experience as a healthcare investor & former McKinsey consultant.
Iancovici brings experience from Qualcomm Life Fund & Novartis/Qualcomm joint venture dRx Capital, while Royston has 15+ years in life sciences investing.